Sandbox Reserved 957: Difference between revisions
No edit summary |
No edit summary |
||
| Line 76: | Line 76: | ||
== References == | == References == | ||
<references/> | <references/> | ||
[1] Francis SH, Zoraghi R, Kotera J, Ke H, Bessay EP, Blount MA, Corbin JD. Phosphodiesterase-5: molecular characteristics relating to structure, function, and regulation. In: Cyclic Nucleotide Phosphodiesterases in Health and Disease, edited by Beavo JA, Houslay MD, Francis SH. Boca Raton, FL: CRC, 2006, p. 131–164.<br \> | |||
Sekiguchi M, Hoshizaki H, Adachi H, Ohshima S, Taniguchi K, Kurabayashi M. Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol. Circ J 68: 610–614, 2004. | |||
Sopory S, Kaur T, Visweswariah SS. The cGMP-binding, cGMPspecific phosphodiesterase (PDE5): intestinal cell expression, regulation and role in fluid secretion. Cell Signal 16: 681–692, 2004.<br \> | |||
Zhu B, Strada S, Stevens T. Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 289: L196–L206, 2005.<br \> | |||